Article Text

Download PDFPDF
Relation between nitric oxide metabolites and haemoglobin concentrations in patients with ischaemic heart disease
  1. Felicita Andreotti1,
  2. Giulio Coluzzi1,
  3. Alberto Lavorgna1,
  4. Francesca Marzo1,
  5. Enrico Di Stasio2,
  6. Cinzia Carrozza2,
  7. Cecilia Zuppi2,
  8. Filippo Crea1
  1. 1Institute of Cardiology, Catholic University, Rome, Italy
  2. 2Institute of Clinical and Chemical Biochemistry, Catholic University, Rome, Italy
  1. Correspondence to:
    Dr F Andreotti
    Institute of Cardiology, Catholic University Medical School, Largo F. Vito 1, 00168 Rome, Italy;felicita.andreotti{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Reduced haemoglobin concentrations ([Hb]) are associated with adverse cardiovascular outcomes in patients with acute coronary syndromes.1 The reasons behind this association may include, in addition to impaired oxygen delivery,1 chronic inflammation,2 reduced erythropoietin activity,1,3 or a general depression of haematopoietic function.4 Indeed, an impoverished circulating reservoir of stem and progenitor cells (PCs) is emerging as a new indicator of cardiovascular risk.4

Nitric oxide (NO), well known for its vasodilatory and antiplatelet actions, is typically reduced in patients with ischaemic heart disease (IHD)5 and may contribute to regulate [Hb]. The type II, cytokine-induced isoform of NO synthase causes haematopoietic suppression in vitro.2 On the other hand, the endothelial (constitutive) type III NO synthase is an essential inducer of marrow cell mobilisation in vivo,6 while the nitric oxide synthase inhibitor, asymmetric dimethylarginine, inhibits the mobilisation, differentiation and function of PCs.5 Moreover, endogenous NO mediates erythropoietin activity3 and promotes the hypoxia inducible factor-1-DNA binding that leads to erythropoietin expression.7

We investigated, in a consecutive series of patients with documented IHD and no known cause of anaemia, whether impaired NO bioavailability (NOx) might be associated with reduced [Hb], possibly helping to explain the adverse outcomes related to lower Hb levels.


Between January and June 2004, 83 patients referred to our Cardiac Care Unit and satisfying our inclusion/exclusion criteria were consecutively enrolled. All patients with documented IHD were eligible for inclusion. …

View Full Text


  • Competing interests: None.